Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028" report has been added to ...

Vancouver, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The global oncolytic virus therapies market size is expected to reach USD 1,546.51 Million at a steady CAGR of 26.2% in 2032, according to latest ...

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

According to a recent study published by Future Market Insights, the market for Oncolytic Virus Cancer Therapy is forecast to reach a valuation of US$ 22.86 Million by 2023-end, and will eventually ...

In a study published Nov. 10 in Nature, the researchers described how they packed two different therapies into a single oncolytic virus—a virus that is used to destroy cancer cells—to hit GBM ...

One type of cancer immunotherapy, called oncolytic viral therapy, works by infecting cancer cells with a specific virus. Some oncolytic viruses occur naturally, while others result from specialized ...

Many oncolytic viruses, including Amgen’s FDA-approved Imlygic, are injected directly into the tumor. In contrast, researchers have shown the immune-evasion capabilities of Vaccinia virus enable ...